Evidence map›Paper›PMID 27483232›Full record

ArticleMolecules (Basel, Switzerland)2016

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies.

Aleksandra Mędra, Magdalena Witkowska, Agata Majchrzak, Barbara Cebula-Obrzut, Michael Y Bonner, Tadeusz Robak, Jack L Arbiser, Piotr Smolewski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Targeting the duality of cancer.NPJ precision oncology · 2017
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Aleksandra MędraDepartment of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. olajeske@o2.pl.
Magdalena WitkowskaDepartment of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. magdamalicka@gmail.com.
Agata MajchrzakDepartment of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. majchrzak_agata@o2.pl.
Barbara Cebula-ObrzutDepartment of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. barbara_cebula@wp.pl.
Michael Y BonnerWinship Cancer Institute, Emory University School of Medicine, 101 Woodruff Cir, Atlanta, GA 30322, USA. mybonne@emory.edu.
Tadeusz RobakDepartment of Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. robaktad@csk.umed.lodz.pl.
Jack L ArbiserWinship Cancer Institute, Emory University School of Medicine, 101 Woodruff Cir, Atlanta, GA 30322, USA. jarbise@emory.edu.
Piotr SmolewskiDepartment of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. piotr_smolewski@wp.pl.
Medical University of Lodz · PLEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Honokiol and triphenylmethanes are small molecules with anti-tumor properties. Recently, we synthesized new honokiol analogues (HAs) that possess common features of both groups. We assessed the anti-tumor effectiveness of HAs in B-cell leukemia/lymphoma cells, namely in chronic lymphocytic leukemia (CLL) cells ex vivo and in pre-B-cell acute lymphoblastic leukemia (Nalm-6), Burkitt lymphoma (BL; Raji), diffuse large B-cell lymphoma (DLBCL; Toledo) and multiple myeloma (MM; RPMI 8226) cell lines. Four of these compounds appeared to be significantly active against the majority of cells examined, with no significant impact on healthy lymphocytes. These active HAs induced caspase-dependent apoptosis, causing significant deregulation of several apoptosis-regulating proteins. Overall, these compounds downregulated Bcl-2 and XIAP and upregulated Bax, Bak and survivin proteins. In conclusion, some of the HAs are potent tumor-selective inducers of apoptosis in ex vivo CLL and in BL, DLBCL and MM cells in vitro. Further preclinical studies of these agents are recommended.

Indexed as

Allyl CompoundsAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsBiphenyl CompoundsCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHumansLeukemiaLignansLymphomaMultiple MyelomaPhenolsAllyl CompoundsAntineoplastic AgentsApoptosis Regulatory ProteinsBiphenyl CompoundshonokiolLignansPhenolstriphenylmethaneTriphenylmethyl CompoundsALLBLCLLDLBCLhonokiol analoguesMM

Identifiers

PMID27483232
PMCPMC6274336
OpenAlexW2500041125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.